BusinessActinium to Present at The Rodman & Renshaw 19th Annual Global Investment ConferenceBy Nasdaq OMXSep 6, 2017, 8:05 PM UTC
BusinessActinium Pharmaceuticals to Participate in the Oppenheimer & Co. Boston Oncology Insights Summit on August 16-17, 2017By Nasdaq OMXAug 9, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals Issues Mid-Year Letter to Shareholders Highlighting Accomplishments and Significant Value Enumerating Catalysts Over the Coming QuartersBy Nasdaq OMXJun 15, 2017, 12:30 PM UTC
BusinessActinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-BBy Nasdaq OMXJun 12, 2017, 11:00 AM UTC
BusinessActinium Pharmaceuticals Announces Appointment of Sandesh Seth as Chief Executive OfficerBy Nasdaq OMXJun 9, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Actimab-ABy Nasdaq OMXMay 24, 2017, 1:26 PM UTC
BusinessActinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Actimab-ABy Nasdaq OMXMay 24, 2017, 1:26 PM UTC
BusinessActinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Actimab-ABy Nasdaq OMXMay 24, 2017, 1:26 PM UTC
